Working Agenda Social

    • Social, for workingagenda.com
Illustration of a bird flying.
  • testing3

    Just a test.

    November 26, 2022
  • Risiplam and the FDA Rare Pediatric Disease Priority Review Voucher

    When  risdiplam was approved by the FDA on August 7, 2020, the FDA announced it had also awarded a Rare Pediatric Disease Priority Review Voucher.  These vouchers are tradable, and have a value of roughly $100 million. The FDA granted this application fast track designation and priority review. The drug also received orphan drug designation,…

    November 26, 2022
  • Access limited for SMA treatments

    Access for risiplam is limited in many countries. These are a few of the family fundraising pages. Poland.  https://www.gofundme.com/f/help-emilia-dembinska-sma-type-1 https://www.gofundme.com/f/hira-nur-sma-type2 India. https://milaap.org/fundraisers/support-keya-hatkar UK. https://www.gofundme.com/f/Support-Twins-Raffy-and-Siddys-SMA-1-Fight        

    November 26, 2022
  • Youtube video on setting up a server on WordPress

    https://www.youtube.com/watch?v=uFBij0-ZrbE&t=688s

    November 26, 2022
  • The Xtandi Bayh-Dole case

    On November 18, 2022, Robert Sachs and Clare Love wrote to HHS Secretary Becerra, urging him to act on their patent to use US government rights in three patents on the prostate cancer drug Xtandi. Average Wholesale Price (AWP) price in the USA is $189,800 per year, 3 to 7 times the price is all…

    November 22, 2022

Working Agenda Social

Proudly powered by WordPress